ForPatients
by Roche

Spinal Muscular Atrophy (SMA)

Bioavailability and Bioequivalence of Two Risdiplam Tablets in Healthy Participants

Trial Status	Trial Runs In	Trial Identifier
Completed	1 Countries	NCT04718181 BP42066

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

The study is a randomized, single oral dose, crossover study in up to three parts to investigate the relative bioavailability and bioequivalence of two different formulations of risdiplam 5 mg (dispersible tablets) versus the current risdiplam oral solution formulation in healthy male and female participants. The effect of food on these two dispersible tablets and the current oral solution will be studied, as well as the effect of omeprazole on the dispersible tablets.

Hoffmann-La Roche Sponsor	**Phase 1** Phase

NCT04718181 BP42066
Trial Identifiers

Eligibility Criteria:

Gender	Age	Healthy Volunteers
All	>=18 Years & <= 55 Years	Accepts Healthy Volunteers